Method for treating neoadjuvant chemotherapy-induced metastasis
View Patent ↗Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using Tie-2 inhibitors. Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using inhibitors of Mena expression and/or function are also provided.
1. A method of treating a subject for a breast cancer tumor, wherein the subject has received or is receiving chemotherapy treatment for the breast cancer tumor, comprising
a) identifying the subject as having an increased risk of metastasis in response to chemotherapy by performing or having performed a quantification of Mena Calc , Mena INV or a TMEM score of the tumor, and comparing to a predetermined control level of Mena Calc , Mena INV or TMEM score, wherein a subject having a Mena Calc , Mena INV or a TMEM score above the respective predetermined control level identifies the subject as having an increased risk of metastasis, and
b) when a subject is identified in step a) as having an increased risk of metastasis in response to chemotherapy, either (1) ceasing chemotherapy on the subject and administering a targeted therapy, immunotherapy or radiotherapy to treat the cancer, or (2) administering a chemotherapy and an amount of (i) a Tie-2 inhibitor effective to reduce chemotherapy-induced metastasis or chemotherapy-induced cancer cell dissemination, or (ii) a TMEM activity inhibitor, to the subject effective to treat the tumor.
2. The method of claim 1 , wherein when a subject is identified in step a) as having an increased risk of metastasis in response to chemotherapy, the chemotherapy and an amount of (i) a Tie-2 inhibitor effective to reduce chemotherapy-induced metastasis or chemotherapy-induced cancer cell dissemination, or (ii) a TMEM activity inhibitor, is administered to the subject.
3. The method of claim 1 , wherein the TMEM activity inhibitor comprises a CSF1R inhibitor, a VEGFR inhibitor, or a MENA inhibitor.
4. The method of claim 1 , further comprising obtaining a predetermined control level for Mena Calc , Mena INV or TMEM score for the subject by obtaining a Mena Calc , Mena INV or TMEM score from a tumor sample from the subject prior to any chemotherapy being initiated on the subject.
5. The method of claim 1 , wherein the Tie- 2 inhibitor is rebastinib (4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide).
6. The method of claim 1 , wherein the chemotherapy is an anti-tubulin chemotherapy.
7. The method of claim 1 , wherein the chemotherapy is a taxane.
8. The method of claim 1 , wherein the chemotherapy is paclitaxel or eribulin.
9. The method of claim 1 , wherein the breast cancer is an adenocarcinoma.
10. The method of claim 1 , wherein the breast cancer is Human Epidermal Growth Factor 2 Negative.
11. The method of claim 1 , wherein the breast cancer is a Stage IV breast cancer.
12. The method of claim 1 , wherein the chemotherapy is a neoadjuvant therapy.
13. The method of claim 1 , wherein the metastasis is a lung metastasis, bone metastasis, lymph node metastasis, liver metastasis or brain metastasis.
14. The method of claim 12 , wherein the chemotherapy is a neoadjuvant therapy.
15. The method of claim 12 , wherein the neoadjuvant therapy comprises doxorubicin and cyclophosphamide.
16. The method of claim 1 , wherein the subject has been identified as likely having a poor long-term response to chemotherapy by comprising determining, in a sample obtained from the subject, the level of Mena Calc , Mena INV or a TMEM score thereof, and comparing to a predetermined control level of Mena Calc , Mena INV or TMEM score, respectively, and identifying the subject as having a poor long-term response to chemotherapy wherein a subject is identified as likely having a poor long-term response to chemotherapy when the sample obtained from the subject has a level of Mena Calc , Mena INV or TMEM score above the predetermined control level of Mena Calc , Mena INV or TMEM score, respectively.
17. The method of claim 1 , wherein the subject has been identified as likely having a tumor resistant to a receptor tyrosine kinase (RTK) inhibitor therapy by comprising determining, in a sample of the tumor obtained from the subject, the level of Mena Calc , Mena INV or a TMEM score thereof, and comparing to a predetermined control level of Mena Calc , Mena INV or TMEM score, respectively, and identifying the subject as having a tumor resistant to RTK inhibitor therapy, wherein a subject is identified as likely having a tumor resistant to RTK inhibitor therapy when the sample obtained from the subject has a level of Mena Calc , Mena INV or TMEM score above the predetermined control level of Mena Calc , Mena INV or TMEM score, respectively.
18. The method of claim 1 , wherein the subject is a human patient or subject.